In addition, we previously showed that in SF3B1 mutated MDS del(5q) and/or RUNX1 mutations have a negative impact on outcome while a BM blast threshold of <5%, which is used by ICC and WHO 2022, has no independent impact on OS [15]. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.